CMD22 Capital Markets Day

8 Commercial execution and innovation NASH and Alzheimer's disease Novo NordiskⓇ NASH patient journey underscores key barriers to overcome for Novo Nordisk to be successful ~22 million people are expected to live with NASH F2-F4c by 2030 Hurdles 25 20 20 NASH 15 prevalence 10 Low disease awareness Inadequate patient No treatment referrals¹ options No prognostic biomarker Few patients receiving diagnosis 5 0 Prevalence Diagnosed Access • Build strong presence . Create urgency to treat in NASH Build strong speciality-referral process Engage Endos, Hepas and PCPS Indicates expected invesment level . Market preparation priorities Increase diagnosis rate Momentum towards NITs in clinical practice and guidelines NITs for diagnosis, screening and monitoring NASH: Non-alcoholic steatohepatitis; Endos: endocrinologist; PCP: primary care physician; NIT: Non-invasive tests; 'Referrals and identification; Hepas: hepatologists; F: Fibrosis stage Source: Estes C, Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatology, 2018 Evidence generation Build understanding of importance of addressing underlying cause of disease Stop clinical progression amongst physicians and payers CMD22 CAPITAL MARKETS DAY

View entire presentation